Rexahn Pharmaceuticals, Inc.  

(Public, NYSEMKT:RNN)   Watch this stock  
Find more results for NYSEAMEX:RNN
0.222
+0.003 (1.51%)
Sep 26 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.22 - 0.22
52 week 0.20 - 0.64
Open 0.22
Vol / Avg. 783,714.00/718,506.00
Mkt cap 52.74M
P/E     -
Div/yield     -
EPS -0.07
Shares 237.23M
Beta -0.06
Inst. own 14%
Nov 1, 2016
Q3 2016 Rexahn Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Sep 12, 2016
Rexahn Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Aug 8, 2016
Q2 2016 Rexahn Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -30.74% -49.31%
Return on average equity -42.89% -63.43%
Employees 20 -
CDP Score - -

Address

15245 Shady Grove Rd Ste 455
ROCKVILLE, MD 20850-7203
United States - Map
+1-240-2685300 (Phone)
+1-240-2685310 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Officers and directors

Peter C. Brandt Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Chang H. Ahn Chairman Emeritus, Chief Scientist
Age: 63
Bio & Compensation  - Reuters
Peter D. Suzdak Ph.D. Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Tae Heum Jeong Chief Financial Officer, Secretary
Age: 44
Bio & Compensation  - Reuters
Ely Benaim Chief Marketing Officer
Age: 54
Bio & Compensation  - Reuters
Charles G. Beever Independent Director
Age: 62
Bio & Compensation  - Reuters
Mark P. Carthy Independent Director
Age: 54
Bio & Compensation  - Reuters
Kwang Soo Cheong Independent Director
Age: 54
Bio & Compensation  - Reuters
Richard J. Rodgers Independent Director
Age: 48
Bio & Compensation  - Reuters